BioCentury | Mar 22, 2018
Targets & Mechanisms

PureTech’s lymphatic leap

PureTech Health plc is launching a new branch of inquiry into the lymphatic system following discoveries that the network extends into the brain and could be used to deliver immunotherapies directly to tissues. While research...
BioCentury | Feb 9, 2018
Product R&D

R is for readout

...III AZD7986 (INS1007) dipeptidyl peptidase-1 (DPP-1; CTSC)-inhibitor Non-cystic fibrosis bronchiectasis Phase II AZD5718 5-lipoxygenase activating protein (FLAP; ALOX5AP...
BioCentury | May 23, 2017
Regulation

Misalignment in autism

FDA ’s Patient-Focused Drug Development meeting on autism revealed two different stakeholder groups with rather different priorities. Individuals with autism who were able to speak on their own behalf said their primary concerns are not...
BioCentury | Feb 25, 2016
Distillery Techniques

Techniques: In vivo reprogramming of stomach cells into insulin-secreting pancreatic β-like cells

...as reprogramming factors under the control of a doxycycline-inducible promoter. When transplanted into the omental flap...
BioCentury | Jan 29, 2015
Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

...Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that...
...inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP...
...include testing AZD6642 in animal models of asthma and other inflammatory indications. TARGET/MARKER/PATHWAY: 5-lipoxygenase activating protein (FLAP; ALOX5AP...
BioCentury | May 22, 2014
Tools & Techniques

A big heart

...fat layer." Philippe Menasche liked the idea of optimizing stem cell delivery by a pericardial flap...
...human Embryonic Stem Cell-derived prOgenitors in severe heaRT failure) trial is recruiting patients. "The pericardial flap...
BioCentury | Nov 25, 2013
Clinical News

TissuGlu Surgical Adhesive regulatory update

...module of a PMA to FDA for TissuGlu Surgical Adhesive for fluid management during large flap...
BioCentury | Sep 12, 2011
Company News

Amira, Bristol-Myers deal

...spun out two companies with assets from Amira: FLAP LLC; and Panmira Pharmaceuticals LLC . FLAP...
...which in-licensed Amira's 5-lipoxegenaxe activating protein (FLAP; ALOX5AP ) inhibitors in 2008. One of the FLAP...
BioCentury | Sep 10, 2011
Company News

Bristol-Myers spins out Amira assets

...I testing for asthma and chronic obstructive pulmonary disease (COPD). The pharma also spun out FLAP...
...from Amira-partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). In 2008, GSK in-licensed Amira's 5-lipoxegenaxe activating protein (FLAP; ALOX5AP...
BioCentury | Aug 1, 2011
Strategy

Therapeutically adjacent

...two of Amira's 5-lipoxygenase activating protein ( FLAP ; ALOX5AP ) inhibitors in 2008. One of the FLAP...
...5-lipoxygenase ( ALOX5 ; 5-LO ) inhibitor program and rights to topical uses of additional FLAP...
Items per page:
1 - 10 of 71